# Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma

> **NCT05790200** · PHASE2 · UNKNOWN · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 30 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Cadonilimab

## Key facts

- **NCT ID:** NCT05790200
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-01
- **Primary completion:** 2025-09-22
- **Final completion:** 2025-09-22
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05790200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05790200, "Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05790200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*